An abridged version of the REVEAL risk calculator, the REVEAL Lite 2, represents a simpler and accurate tool for predicting mortality risk in patients with pulmonary arterial hypertension.
Oral combination therapy does not appear to help achieve or maintain low risk status in most treatment-naive patients with pulmonary arterial hypertension.
Pulmonary arterial compliance was found to be strongly associated with all-cause mortality and clinical worsening in patients with systemic lupus erythematosus-associated pulmonary arterial hypertension.
PAH associated with CHD is linked to significant reductions in survival and quality of life, especially for patients progressing to Eisenmenger syndrome.
Although higher body mass index is causally associated with higher pulmonary artery pressure, it is not associated with pulmonary vascular remodeling.
Treatment with LIQ861, an inhaled dry-powder form of treprostinil, was associated with significant improvements in several clinical and quality of life measures in patients with pulmonary arterial hypertension.
The emPHasis-10 health-related quality of life measure is an effective prognostic tool that can stratify patients with pulmonary arterial hypertension based on mortality risk.
The right ventricular strain-area loop can independently predict 5-year all-cause mortality in patients with precapillary pulmonary hypertension.
Older patients with pulmonary arterial hypertension may have lower pulmonary artery compliance and worse right ventricular performance compared with their younger counterparts.
Balloon pulmonary angioplasty and pulmonary vasodilators were both found to improve functional and hemodynamic outcomes in patients with inoperable chronic thromboembolic pulmonary hypertension.
